The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with CAR-T cell therapies. As described in the patent application, STAR-LLD's ...
The first half of this article explored the fundamental principles of friction and wear in plastics, as well as the importance of selecting the right base polymer. While a polymer’s inherent ...
CAS-ViT: Convolutional Additive Self-Attention Vision Transformers for Efficient Mobile Applications
Abstract: Vision Transformers (ViTs) mark a revolutionary advance in neural networks with their token mixer’s powerful global context capability. However, the pairwise token affinity and complex ...
–Application is based on results from the phase 3 STELLAR-303 pivotal trial, in which zanzalintinib in combination with atezolizumab improved median overall survival and significantly reduced the risk ...
FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating ...
Significant Unmet Need Remains; Over 14,000 U.S. Patients Eligible for Treatment Each Year in This Setting MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (SMMT) ("Summit," "we," or the "Company") ...
Company to Initiate First-in-Human Phase 1 Clinical Trial in Q2 2026 ROCKVILLE, Md.--(BUSINESS WIRE)--#Clinicaltrials--Immunomic Therapeutics, Inc. (“ITI”), a privately held clinical-stage ...
SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results